The operative piece of your description is what I italicized. It is utterly amazing how magical their drug is. So much so that after every biotech trend wave hits they can claim efficacy in that disease or that MOA. HCV circa 2010ish, yep they could do that! Immuno Onc in the ipilimumab era? Yep! Ebola in 2014? Yep!
I give it a 50/50 that in the next year something comes out from them hinting at checkpoint activity or fatty liver potential. (Thankfully I see no way for them to claim CAR-T, but Bi-Specifics...? Can't rule that out entirely.)
There are a whole class of companies that do this, but PPHM is clearly up there with the best of them. And probably what GrthzGd was referring to.
Add to this their clinical trial acumen and they are definitely a first rate 'science' company.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.